WEDNESDAY, SEPTEMBER 28, 2016

Soligenix's Macrophage Activation Syndrome study shows promise

Soligenix, Inc., a biopharmaceutical company that focuses on biodefense, inflammation, and oncology, recently completed a successful study of a Macrophage Activation Syndrome (MAS) treatment.

MAS is a rare complication of some childhood rheumatological disorders. Scientists believe that MAS is caused by the unregulated overproduction of immune system cells (specifically macrophages and T lymphocytes). There are so many of these immune system cells that they begin to attack the body’s own tissues and cells.

MAS occurs in approximately 10 percent of chronic rheumatic patients. Patients with systemic juvenile idiopathic arthritis are also affected by MAS.

Experts estimate MAS mortality rates stand at 10 to 20 percent.

A common feature of MAS is the reduction of white blood cells, red blood cells and platelets in the patient’s blood (called pancytopenia). Patients also suffer from liver insufficiency, neurological symptoms and coagulopathy.

Soligenix's study was an animal model of SGX94,  an inherent defense regulator (IDR) technology.

The study showed that SGX94 successfully combats pancytopenia, which may be key to solving the disease.

SGX94 increased platelets and white blood cells, fighting pancytopenia symptoms.

"The efficacy of SGX94 in this animal model of MAS further confirms the broad potential of the IDR platform across multiple inflammatory and infectious diseases, particularly in light of the excellent safety profile observed with SGX94 to date in humans," Christopher J. Schaber, president and chief executive officer of Soligenix, said. "Soligenix will continue to evaluate the potential clinical applicability of SGX94 in MAS as well as other indications. Soligenix will also pursue government grant support to fund the further development of this rare and serious inflammatory complication."